Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow in Hematology-Oncology, Medicine, Duke University 2008
  • Fellow in Hematology-Oncology, Medicine, University of Pennsylvania 2005 - 2007
  • Resident, Medicine, University of North Carolina at Chapel Hill 2001 - 2004
  • M.D., Drexel University 2001
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Hematology, Medicine 2008 - 2012
  • Instructor, Temporary in the Department of Medicine, Medicine, Hematology, Medicine 2008
• Research
• 

  Selected Grants

  • Phase IV open label study of Emicizumab Prophylaxis in Hemophila A patients undergoing minor surgery 2018 - 2021
  • Follow-up Study for Patients who Completed Study ALX0681-C301 (Post-HERCULES) 2016 - 2021
  • Prospective Randomized open blinded end-point (PROBE) study 2018 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • Transfusion Medicine and Hematology awarded by National Institutes of Health 1975 - 2021
  • POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A 2016 - 2020
  • Edoxaban in VTE Associated with Cancer Hokusai VTE Cancer Study DU176b-D-U311 2015 - 2020
  • An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas in the management of pediatric patients who require therapeutic plasma exchange 2017 - 2019
  • OMS721 in TMA 2014 - 2019
  • ART Study (Rituximab as adjunct therapy with plasma exchange in TTP patients) awarded by Washington University School of Medicine 2015 - 2019
  • Microfluidic quartz resonator based blood plasma coagulation monitors 2017 - 2018
  • A Phase III Trial with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura 2016 - 2017
  • RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial 2015 - 2017
  • Public Health Surveillance of Bleeding 2011 - 2016
  • GSK AML 2013 - 2016
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Scully, Marie, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, et al. “Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura..” N Engl J Med 380, no. 4 (January 24, 2019): 335–46. https://doi.org/10.1056/NEJMoa1806311.
       Full Text  Link to Item
    • Onwuemene, Oluwatoyosi A., Steven C. Grambow, Chetan B. Patel, Robert J. Mentz, Carmelo A. Milano, Joseph G. Rogers, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study..” J Clin Apher 33, no. 4 (August 2018): 469–79. https://doi.org/10.1002/jca.21622.
       Full Text  Link to Item
    • Diep, Robert, and Ara Metjian. “A rare CALR variant mutation and a review of CALR in essential thrombocythemia..” J Thromb Thrombolysis 45, no. 3 (April 2018): 457–62. https://doi.org/10.1007/s11239-018-1619-0.
       Full Text  Link to Item
    • Tanhehco, Yvette C., Gowthami Arepally, and Ara Metjian. “Novel therapeutic approaches for thrombotic thrombocytopenic purpura..” Curr Opin Hematol 24, no. 6 (November 2017): 521–28. https://doi.org/10.1097/MOH.0000000000000375.
       Full Text  Link to Item
    • Abbes, Sarah, Ara Metjian, Alice Gray, Tereza Martinu, Laurie Snyder, Dong-Feng Chen, Matthew Ellis, Gowthami M. Arepally, and Oluwatoyosi Onwuemene. “Human Leukocyte Antigen Sensitization in Solid Organ Transplantation: A Primer on Terminology, Testing, and Clinical Significance for the Apheresis Practitioner..” Ther Apher Dial 21, no. 5 (October 2017): 441–50. https://doi.org/10.1111/1744-9987.12570.
       Full Text  Link to Item
    • Metjian, Ara, Yvette C. Tanhehco, Nicole Aqui, Vijay G. Bhoj, Lita Jamensky, Marisa B. Marques, Oluwatoyosi Onwuemene, Huy P. Pham, and Gowthami M. Arepally. “The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network..” J Clin Apher 31, no. 5 (October 2016): 448–53. https://doi.org/10.1002/jca.21437.
       Full Text  Link to Item
    • Metjian, Ara D. “rVWF: treatment finally reaches the modern age..” Blood 126, no. 17 (October 22, 2015): 1975–76. https://doi.org/10.1182/blood-2015-08-664052.
       Full Text  Link to Item
    • Nipp, Ryan, Aaron Mitchell, Allyson Pishko, and Ara Metjian. “Waldenström macroglobulinemia in hepatitis C: case report and review of the current literature..” Case Rep Oncol Med 2014 (2014). https://doi.org/10.1155/2014/165670.
       Full Text  Link to Item
    • Patil, Avinash S., Sarah K. Dotters-Katz, Ara D. Metjian, Andra H. James, and Geeta K. Swamy. “Use of a thrombopoietin mimetic for chronic immune thrombocytopenic purpura in pregnancy..” Obstet Gynecol 122, no. 2 Pt 2 (August 2013): 483–85. https://doi.org/10.1097/AOG.0b013e31828d5b56.
       Full Text  Link to Item
    • Sood, S. L., A. Cuker, C. Wang, A. D. Metjian, E. Y. Chiang, J. M. Soucie, B. A. Konkle, and B. A. HTCN Study Investigators. “Similarity in joint function limitation in Type 3 von Willebrand's disease and moderate haemophilia A..” Haemophilia 19, no. 4 (July 2013): 595–601. https://doi.org/10.1111/hae.12119.
       Full Text  Link to Item
    • Silbermins, D., and A. D. Metjian. “Hematology,” December 1, 2012, 404–48. https://doi.org/10.1016/B978-0-323-06398-2.00015-1.
       Full Text
    • Lee, G., W. Duan-Porter, and Ara D. Metjian. “Acquired, non-amyloid related factor X deficiency: review of the literature..” Haemophilia : The Official Journal of the World Federation of Hemophilia 18, no. 5 (September 2012): 655–63. https://doi.org/10.1111/j.1365-2516.2012.02773.x.
       Full Text
    • Whitlatch, Nicole L., David F. Kong, Ara D. Metjian, Gowthami M. Arepally, and Thomas L. Ortel. “Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia..” Blood 116, no. 10 (September 9, 2010): 1761–66. https://doi.org/10.1182/blood-2010-01-262659.
       Full Text  Link to Item
    • Metjian, A. D., C. Wang, S. L. Sood, A. Cuker, S. M. Peterson, J. M. Soucie, B. A. Konkle, and B. A. HTCN Study Investigators. “Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease..” Haemophilia 15, no. 4 (July 2009): 918–25. https://doi.org/10.1111/j.1365-2516.2009.02025.x.
       Full Text  Link to Item
    • Metjian, Ara, and Charles S. Abrams. “New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents..” Biologics 3 (2009): 499–513.
       Link to Item
    • Metjian, Ara, and Wendy Lim. “ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?.” Hematology Am Soc Hematol Educ Program, 2009, 247–49. https://doi.org/10.1182/asheducation-2009.1.247.
       Full Text  Link to Item
    • Metjian, Ara, and Charles S. Abrams. “New insights and therapeutics for immune-mediated thrombocytopenia..” Expert Rev Cardiovasc Ther 6, no. 1 (January 2008): 71–84. https://doi.org/10.1586/14779072.6.1.71.
       Full Text  Link to Item
    • Metjian, A., R. L. Roll, A. D. Ma, and C. S. Abrams. “Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus..” J Biol Chem 274, no. 39 (September 24, 1999): 27943–47. https://doi.org/10.1074/jbc.274.39.27943.
       Full Text  Link to Item
    • Ma, A. D., A. Metjian, S. Bagrodia, S. Taylor, and C. S. Abrams. “Cytoskeletal reorganization by G protein-coupled receptors is dependent on phosphoinositide 3-kinase gamma, a Rac guanosine exchange factor, and Rac..” Mol Cell Biol 18, no. 8 (August 1998): 4744–51. https://doi.org/10.1128/mcb.18.8.4744.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.